{
  "abstract": "Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the nigrostriatal pathway. Current treatments for PD primarily provide symptomatic relief through dopamine replacement; however, no neuroprotective drugs are currently clinically available. Our previous work demonstrated that meloxicam (MLX) protects against 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in human neuroblastoma SH-SY5Y cells via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, independent of cyclooxygenase inhibition. However, the downstream mechanisms remain unclear. In this study, we examined which anti-apoptotic B-cell lymphoma-2 (Bcl-2) family proteins, including Bcl-2, Bcl-xL, and myeloid cell leukemia 1 (Mcl-1), contribute to MLX-mediated neuroprotection. We also evaluated whether post-treatment with MLX can rescue MPP+-induced neurotoxicity, considering its potential clinical applicability. Cell viability assays and Western blotting were performed to assess neuronal survival and protein expression. Our results show that post-treatment with MLX restored neuronal viability after MPP+ exposure through the PI3K/Akt/Mcl-1 pathway, indicating that MLX can attenuate MPP+-induced apoptotic progression even when administered at delayed time points. These findings elucidate the molecular basis of MLX-mediated neuroprotection and support the potential therapeutic repurposing of MLX as a neuroprotective agent for PD.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "name": "Yasuhiro Matsuura"
    },
    {
      "name": "Takayuki Manabe"
    },
    {
      "name": "Tomoko Ohkubo"
    },
    {
      "name": "Masaya Kanda"
    },
    {
      "name": "Kuninori Iwayama"
    },
    {
      "name": "Naoya Kamiyama"
    },
    {
      "name": "Masayuki Chuma"
    },
    {
      "name": "Yoshikazu Tasaki"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/202h4zg2903jx.bib",
  "cited_by": 0,
  "doi": "10.1248/bpb.b26-00348",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00348/_article",
  "id": "202h4zg2903jx",
  "issns": [
    "1347-5215",
    "0918-6158"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00348/_article",
  "language": null,
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/pharmacology-toxicology"
    ],
    [
      "openalex",
      "2728|Parkinson's Disease Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7223220912",
  "pdf_url": "https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00348/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-23",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/202h4zg2903jx.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:32Z",
      "native_id": "10.1248/bpb.b26-00348",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00348/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Parkinson's Disease Mechanisms and Treatments",
      "subfield": "neurology"
    }
  ],
  "title": "Post-treatment with Meloxicam Attenuates MPP⁺-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1",
  "title_text": "Post-treatment with Meloxicam Attenuates MPP⁺-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:32Z",
  "url": "https://research.draconitic.com/paper/202h4zg2903jx",
  "venue": "Biological and Pharmaceutical Bulletin",
  "versions": []
}